UPDATE: pSivida's therapy candidate for chronic non-infectious posterior uveitis achieves main goal in Phase III trial; shares jump
Shares in drug maker pSivida (Nasdaq: PSDV) surged to close up over 21% on the Nasdaq after the company said its said late-stage trials for its lead experimental therapy prevented inflammation in the back of patients' eyes.
The company said Phase III trials for its injectable micro-insert Medidur to treat chronic non-infectious posterior uveitis with 129 patients randomized to receive treatment with Medidur or placebo injection.
About 18.4% of Medidur-treated eyes experienced posterior uveitis recurrence at six-months of follow-up compared to 78.6% of control eyes. Meanwhile, 23% of Medidur-treated eyes versus 4.9% of control eyes showed improvement in visual acuity gaining 15 or more letters from baseline on the Early Treatment Diabetic Retinopathy Study eye chart.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze